Part IV: Effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: A post-marketing surveillance study in Germany

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 3, 2005, Pages

  Diener, Hans Christoph ^a   Gendolla, Astrid ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Daily activities; Headache pain; Migraine related disability; Tolerability; Zolmitriptan orally disintegrating tablet

Indexed keywords

ANTIMIGRAINE AGENT; ZOLMITRIPTAN;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DAILY LIFE ACTIVITY; DISABILITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; GERMANY; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MOOD DISORDER; MYALGIA; NAUSEA; ORALLY DISINTEGRATING TABLET; PAIN; PARESTHESIA; POSTMARKETING SURVEILLANCE; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TABLET DISINTEGRATION; TACHYCARDIA; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADULT; FEMALE; GERMANY; HUMANS; MALE; MIGRAINE DISORDERS; OXAZOLIDINONES; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 23844462862     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46296     Document Type: Article

References (15)

1. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998;50:1741-5
2. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-43
3. International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998;38:173-83
4. Klapper J, Charlesworth B, Soisson T, et al. Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain-free response rates and prevents progression to more severe migraine in patients with significant migraine-related disability. Headache 2002;42:395
5. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996;167:355-9
6. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997;49:1210-18
7. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997;49:1219-25
8. Gallagher RM, Dennish G, Spierings EL, et al. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000;40:119-28
9. Nappi G, Johnson FN. The clinical efficacy of zolmitriptan. Reviews in Contemporary Pharmacotherapy 2000;11:99-118
10. Ryan REJ, Diamond S, Giammarco RA, et al. Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence. CNS Drugs 2000;13:215-26
11. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002;22:101-6
12. Spierings E, Dodick D, Pearlman E, et al. Zolmitriptan orally disintegrating tablet shows significant efficacy as early as 30 minutes and high sustained response rates: results of a large placebo-controlled trial. Cephalalgia 2002;22:PB 26
13. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56(Suppl 1):S20-S28
14. Rapoport AM, Dowson AJ, Charlesworth B, et al. Zolmitriptan conventional and orally disintegrating tablets achieve headache response as early as 30 minutes post-treatment: results of a pooled data analysis. Neurology 2003;60(Suppl 1):236
15. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int J Clin Pract 2003;57:573-6